Last updated: June 25, 2024
Sponsor: Akili Interactive Labs, Inc.
Overall Status: Active - Not Recruiting
Phase
N/A
Condition
Attention Deficit/hyperactivity Disorder (Adhd - Adults)
Treatment
EndeavorRx
Clinical Study ID
NCT05991167
Akili-060
All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Are prescribed EndeavorRx by their healthcare provider as part of routine clinicalpractice
Provide informed consent/assent to participate in the registry
Exclusion
Exclusion Criteria:
- N/A
Study Design
Total Participants: 150
Treatment Group(s): 1
Primary Treatment: EndeavorRx
Phase:
Study Start date:
June 01, 2022
Estimated Completion Date:
December 31, 2025
Study Description
Connect with a study center
Akili Interactive Labs, Inc.
Boston, Massachusetts 02110
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.